Ibutilide
As of the edition of 20 October 2026, Ibutilide is a small molecule: marketed, first approved in 1995 (US); acts on KCNH2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2000
- Kind
- Small molecule
- Brand name
- Corvert
- First approved
- 28 December 1995 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Pfizer
- Registered trials
- 7, 1 stopped early
- Disease areas
- Heart and blood vessels; Inherited and neonatal
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KCNH2 | Voltage-gated inwardly rectifying potassium channel KCNH2 | Q12809 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 0 | 1 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 4 | 3 | 3 | 0 | 0 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant | 1995 to now |